REPL
Replimune Group, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +10.0% ·
share flow -9.5% ·
net new positions +9.1%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 75 | +2 | 45.55M | $503.98M | +13 | −11 |
| Q1 2026 | 75 | +4 | 41.32M | $315.89M | +10 | −6 |
| Q4 2025 | 71 | +3 | 45.45M | $441.76M | +3 | — |
| Q3 2025 | 15 | -4 | 32.26M | $135.16M | — | −4 |
| Q2 2025 | 16 | 0 | 29.86M | $277.39M | — | — |
| Q1 2025 | 13 | 0 | 20.78M | $202.64M | — | — |
| Q4 2024 | 13 | +1 | 19.63M | $237.78M | +2 | −1 |
| Q3 2024 | 11 | +1 | 14.48M | $158.71M | +1 | — |
| Q2 2024 | 10 | — | 16.01M | $144.07M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 9.88M | +7.0% | $108.28M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 9.88M | +7.0% | $108.28M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.43M | +17.9% | $15.66M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 1.43M | +17.9% | $15.66M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Millennium Management ✦ | 1.15M | -63.0% | $12.66M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | D. E. Shaw & Co. ✦ | 867.68K | -6.9% | $9.51M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 867.68K | -6.9% | $9.51M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | Norges Bank ✦ (passive) | 379.40K | -17.5% | $4.16M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 9 | Wellington Management ✦ | 242.40K | -40.2% | $2.66M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | Wellington Management ✦ | 242.40K | -40.2% | $2.66M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 11 | Two Sigma Investments ✦ | 179.24K | -13.4% | $1.96M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 135.78K | -36.8% | $1.49M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | Renaissance Technologies ✦ | 107.74K | -25.8% | $1.18M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | Fisher Asset Management ✦ | 77.66K | 0.0% | $851,186 | 0.0% | Held | 2 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 27.79K | New | $304,534 | 0.0% | New | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 27.79K | New | $304,534 | 0.0% | New | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 27.79K | New | $304,534 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| AQR Capital Management | $304,534 | 0.0% |
| AQR Capital Management | $304,534 | 0.0% |
| AQR Capital Management | $304,534 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 70.00K shares, $535 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 9.26K sh · $132,176
Officer · 11.45K sh · $148,481
Officer, Director · 39.34K sh · $510,253
Officer · 7.63K sh · $98,987
Officer · 11.45K sh · $148,468
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
11.8% of class · View original SEC filing ↗